Literature DB >> 24061200

GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures.

Shabeesh Balan1, Sanish Sathyan, Saradalekshmi K Radha, Vijai Joseph, Kurupath Radhakrishnan, Moinak Banerjee.   

Abstract

OBJECTIVE: Several antiepileptic drugs (AEDs) are known to target the GABA(A) receptor through positive allosteric modulation of the receptors, thereby enhancing GABA(A) receptor-mediated inhibition. The large diversity of GABA(A) receptors has been reported in the central nervous system; some of these have been implicated in epilepsy susceptibility and AED resistance, which we aimed to examine.
MATERIALS AND METHODS: We investigated the association of single-nucleotide polymorphisms in GABA(A) receptor subunit subtype genes namely; rs2279020 (GABRA1), rs3219151 (GABRA6), rs2229944 (GABRB2), and rs211037 (GABRG2) with predisposition to epilepsy and AED resistance. This was assessed in three cohorts of ethnically matched South Indian ancestry: mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) (prototype of AED-resistant epilepsy syndrome), juvenile myoclonic epilepsy (prototype of AED-responsive epilepsy syndrome), and nonepilepsy controls.
RESULTS: A significant allelic (P=0.0006, odds ratio=1.6, 95% confidence interval=1.22-2.08) and genotypic (P=0.001) association of a synonymous variant in GABRG2, rs211037 (Asn196Asn) was observed with epilepsy irrespective of its phenotype, that is, MTLE-HS or juvenile myoclonic epilepsy. However, this association was not retained in epilepsy patients with a history of febrile seizures. The GABA(A) receptor subunit subtype genes were not found to have any association with AED resistance. In-silico analysis indicated that rs211037 plays a significant role in the transcriptional regulation and splicing regulation.
CONCLUSION: We could substantiate that among the GABA(A) receptor subunit gene cluster polymorphisms, the GABRG2, rs211037 predisposes susceptibility to epilepsy, irrespective of its phenotype, but not to AED resistance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24061200     DOI: 10.1097/FPC.0000000000000000

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  14 in total

1.  Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels.

Authors:  Ruchi Baghel; Sandeep Grover; Harpreet Kaur; Ajay Jajodia; Chitra Rawat; Ankit Srivastava; Suman Kushwaha; Rachna Agarwal; Sangeeta Sharma; Ritushree Kukreti
Journal:  CNS Neurosci Ther       Date:  2016-06-01       Impact factor: 5.243

2.  Expanding the phenotypic spectrum of GABRG2 variants: a recurrent GABRG2 missense variant associated with a severe phenotype.

Authors:  Fanggeng Zou; Kirsty McWalter; Lindsay Schmidt; Amy Decker; Jonathan D Picker; Sharyn Lincoln; David A Sweetser; Lauren C Briere; Chellamani Harini; Eric Marsh; Livija Medne; Raymond Y Wang; Karen Leydiker; Andrew Mower; Gepke Visser; Inge Cuppen; Koen L van Gassen; Jasper van der Smagt; Adeel Yousaf; Michael Tennison; Anita Shanmugham; Elizabeth Butler; Gabriele Richard; Dianalee McKnight
Journal:  J Neurogenet       Date:  2017-05-02       Impact factor: 1.250

3.  Impact of GABAA receptor gene variants (rs2279020 and rs211037) on the risk of predisposition to epilepsy: a case-control study.

Authors:  Maryam Amjad; Atiya Tabassum; Khalid Sher; Suneel Kumar; Sitwat Zehra; Sehrish Fatima
Journal:  Neurol Sci       Date:  2022-02-12       Impact factor: 3.307

4.  Genetic Association of Epilepsy and Anti-Epileptic Drugs Treatment in Jordanian Patients.

Authors:  Laith N Al-Eitan; Islam M Al-Dalala; Afrah K Elshammari; Wael H Khreisat; Aseel F Nimiri; Adan H Alnaamneh; Hanan A Aljamal; Mansour A Alghamdi
Journal:  Pharmgenomics Pers Med       Date:  2020-10-16

5.  Contribution of GABRG2 Polymorphisms to Risk of Epilepsy and Febrile Seizure: a Multicenter Cohort Study and Meta-analysis.

Authors:  Batoul Sadat Haerian; Larry Baum; Patrick Kwan; Stacey S Cherny; Jae-Gook Shin; Sung Eun Kim; Bok-Ghee Han; Hui Jan Tan; Azman Ali Raymond; Chong Tin Tan; Zahurin Mohamed
Journal:  Mol Neurobiol       Date:  2015-10-09       Impact factor: 5.590

Review 6.  Genetic susceptibility in Juvenile Myoclonic Epilepsy: Systematic review of genetic association studies.

Authors:  Bruna Priscila Dos Santos; Chiara Rachel Maciel Marinho; Thalita Ewellyn Batista Sales Marques; Layanne Kelly Gomes Angelo; Maísa Vieira da Silva Malta; Marcelo Duzzioni; Olagide Wagner de Castro; João Pereira Leite; Fabiano Timbó Barbosa; Daniel Leite Góes Gitaí
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

Review 7.  Pharmacogenomic Characterization in Bipolar Spectrum Disorders.

Authors:  Stefano Fortinguerra; Vincenzo Sorrenti; Pietro Giusti; Morena Zusso; Alessandro Buriani
Journal:  Pharmaceutics       Date:  2019-12-21       Impact factor: 6.321

8.  Genetic Polymorphism of GABRG2 rs211037 is Associated with Drug Response and Adverse Drug Reactions to Valproic Acid in Chinese Southern Children with Epilepsy.

Authors:  Jieluan Lu; Hanbing Xia; Wenzhou Li; Xianhuan Shen; Huijuan Guo; Jianping Zhang; Xiaomei Fan
Journal:  Pharmgenomics Pers Med       Date:  2021-09-15

9.  Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistance.

Authors:  Shabeesh Balan; Sumitha Prameela Bharathan; Neetha Nanoth Vellichiramal; Sanish Sathyan; Vijai Joseph; Kurupath Radhakrishnan; Moinak Banerjee
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

10.  Association between Vitamin D Receptor Gene Polymorphisms with Childhood Temporal Lobe Epilepsy.

Authors:  Pei Jiang; Wen-Ye Zhu; Xin He; Mi-Mi Tang; Rui-Li Dang; Huan-De Li; Ying Xue; Li-Hong Zhang; Yan-Qin Wu; Ling-Juan Cao
Journal:  Int J Environ Res Public Health       Date:  2015-10-30       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.